alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 226–250 of 525 studies with an author at Inserm (FR) (page 10 of 21) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association of Type 2 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Diabetes care 2021-09-29

Type 2 diabetes is associated with increased risks of cognitive dysfunction and brain abnormalities. 4 key findings →

Participants: 10,663 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of neuroinflammation 2025-11-24

Neuro-inflammation was not reduced between the neflamapimod and placebo groups, and no change was observed in [18F]-DPA-714 PET. 5 key findings →

Design: randomized controlled trial Participants: 17 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Lancet Neurology 2017-03-27

Researchers conducted a trial to test the effect of omega 3 polyunsaturated fatty acid supplementation and a multidomain intervention, alone or in combination, compared with placebo, on cognitive decline in elderly adults with memory complaints. 3 key findings →

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Movement Disorders 2017-05-03

Here, we present new criteria aimed to optimize early, sensitive, and specific clinical diagnosis of PSP on the basis of currently available evidence. © 2017 International Parkinson and Movement Disorder Society.

Full summary, score breakdown and related studies → Original source Free full text

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Lancet 2020-06-01

Between Feb 1, 2013, and June 28, 2019 (Barcelona), and between June 1, 2009, and Dec 31, 2014 (Cambridge), we included 388 participants with Down syndrome (257 [66%] asymptomatic, 48 [12%] with prodromal Alzheimer's disease, and 83 [21%] with Alzheimer's disease dementia) and 242 euploid controls.

Full summary, score breakdown and related studies → Original source Free full text

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2022-05-26

The proposed novel, pragmatic method to determine CSF biomarker cutoffs for AD does not require assessment of other biomarkers or assumptions concerning the clinical diagnosis of patients. 1 key finding →

Participants: 497 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2024-03-25

This comprehensive analysis demonstrated that the variance in AD blood biomarker concentrations was mainly explained by age, with minor contributions from cognition, brain atrophy, and genetics, conversely to CSF measures. 3 key findings →

Participants: 2,323 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Nature reviews. Neuroscience 2021-11-23

The current conceptualization of Alzheimer disease (AD) is driven by the amyloid hypothesis, in which a deterministic chain of events leads from amyloid deposition and then tau deposition to neurodegeneration and progressive cognitive impairment. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development and Validation of a Cutoff for the Chair Stand Test as a Screening for Mobility Impairment in the Context of the Integrated Care for Older People Program

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2023-01-01

Fourteen- and 16-second cut points for the CST are suitable to identify people at higher risk of functional decline among older adults in Mexico and Toledo, Spain. 5 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association between urate-lowering therapies and cognitive decline in community-dwelling older adults

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Scientific reports 2022-09-12

Long-term use of urate-lowering therapies (ULT) may reduce inflammaging and thus prevent cognitive decline during aging. 3 key findings →

Design: randomized controlled trial Participants: 51 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The Lancet. Neurology 2015-07-23

Interventions that have even quite modest effects at the individual level could drastically reduce the future burden of dementia associated with Alzheimer's disease at the population level. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Brain : a journal of neurology 2005-03-17

Better knowledge of the preclinical phase of Alzheimer's disease would be an important advance to allow earlier treatment of this ominous disease. 2 key findings →

Participants: 1,050 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer's & dementia (New York, N. Y.) 2019-12-18

This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. 4 key findings →

Participants: 883 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Diabetes care 2008-10-22

The observed relation between high triglycerides, diabetes, and vascular dementia emphasizes the need for detection and treatment of vascular risk factors in older individuals in order to prevent the likelihood of clinical dementia. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Immunity 2022-08-04

Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration

✓ Peer-reviewed alzhub usefulness score 58 out of 100. American journal of epidemiology 1996-10-01

Although many studies have found a cross-sectional relation between depression and dementia or depressive symptomatology and cognitive functioning, the direction of the association is still unknown. 4 key findings →

Design: cohort study Participants: 1,600 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Nature genetics 2005-12-20

We report duplication of the APP locus on chromosome 21 in five families with autosomal dominant early-onset Alzheimer disease (ADEOAD) and cerebral amyloid angiopathy (CAA). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Brain : a journal of neurology 2016-11-05

Alzheimer's disease is characterized by the combined presence of amyloid plaques and tau pathology, the latter being correlated with the progression of clinical symptoms. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed